Literature DB >> 31608425

Consequences of the new zolpidem prescription regulations: a cohort study from the French national healthcare database.

J Touchard1, P Sabatier2, G Airagnes3, S Berdot4,2,5, B Sabatier4,2.   

Abstract

PURPOSE: To determine changes in the prevalence of zolpidem consumption since the change in the regulations of prescription. Formulations containing zolpidem were subject to the regulations of narcotics by the French decree of April 7, 2017.
METHODS: Longitudinal cohort study using data from the representative French healthcare database. The main outcome was the prevalence of oral hypnotic drug reimbursement before and after April 2017. The secondary outcome was the change in prescription habits for zolpidem since the decree in long-term users and excessive users.
RESULTS: A total of 81,174 individuals had at least one hypnotic drug reimbursement; among, whom 2143 had at least one reimbursement of zolpidem. Before the decree, 26% had at least one reimbursement of zolpidem, whereas it dropped to 18.4% after the decree. Among the 545 long-term users, the reimbursement of zolpidem was discontinued after the decree for 60.4% and 24.2% retained zolpidem as a treatment. The main replacement drug was zopiclone for 6.4% of them. Among the 1598 excessive users, the reimbursement of zolpidem was stopped after the decree for 16.5% and 56.3% retained zolpidem as a treatment. The main replacement drug was zopiclone for 12.1% of them.
CONCLUSIONS: The French decree had a major impact on the reimbursement of oral zolpidem. Indeed, prescription of the hypnotic was discontinued for half of the long-term users of zolpidem, and just over one-sixth of the excessive users discontinued the prescription of zolpidem after the decree.

Entities:  

Keywords:  Excessive users; Healthcare database; Prescription regulation; Zolpidem

Year:  2019        PMID: 31608425     DOI: 10.1007/s00228-019-02737-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network.

Authors:  Elisabeth Frauger; Vanessa Pauly; Vincent Pradel; Frank Rouby; Jocelyne Arditti; Xavier Thirion; Maryse Lapeyre Mestre; Joëlle Micallef
Journal:  Fundam Clin Pharmacol       Date:  2010-11-16       Impact factor: 2.748

Review 2.  Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey.

Authors:  Caroline Victorri-Vigneau; Eric Dailly; Gwenaëlle Veyrac; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

Review 3.  French health insurance databases: What interest for medical research?

Authors:  G Moulis; M Lapeyre-Mestre; A Palmaro; G Pugnet; J-L Montastruc; L Sailler
Journal:  Rev Med Interne       Date:  2014-12-26       Impact factor: 0.728

4.  The French addictovigilance network clinical assessment: Z-drugs, true false twins.

Authors:  Morgane Rousselet; Fanny Feuillet; Marie Gerardin; Pascale Jolliet; Jean-Benoit Hardouin; Caroline Victorri-Vigneau
Journal:  Expert Opin Drug Saf       Date:  2017-06-28       Impact factor: 4.250

5.  French national health insurance information system and the permanent beneficiaries sample.

Authors:  P Tuppin; L de Roquefeuil; A Weill; P Ricordeau; Y Merlière
Journal:  Rev Epidemiol Sante Publique       Date:  2010-07-03       Impact factor: 1.019

6.  Chronic hypnotic use at 10 years-does the brand matter?

Authors:  Yochai Schonmann; Or Goren; Ronen Bareket; Doron Comaneshter; Arnon D Cohen; Shlomo Vinker
Journal:  Eur J Clin Pharmacol       Date:  2018-08-08       Impact factor: 2.953

7.  [Dependency of non-benzodiazepine hypnotics. Two case reports].

Authors:  A Ströhle; I A Antonijevic; A Steiger; A Sonntag
Journal:  Nervenarzt       Date:  1999-01       Impact factor: 1.214

Review 8.  Benzodiazepine Misuse in the Elderly: Risk Factors, Consequences, and Management.

Authors:  Guillaume Airagnes; Antoine Pelissolo; Mélanie Lavallée; Martine Flament; Frédéric Limosin
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

9.  Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey.

Authors:  Olivia Boeuf; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.

Authors:  Patrick Blin; Caroline Dureau-Pournin; Regis Lassalle; Abdelilah Abouelfath; Cécile Droz-Perroteau; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2015-12-28       Impact factor: 4.335

View more
  2 in total

1.  Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?

Authors:  Alexandra Jobert; Marion Istvan; Edouard-Jules Laforgue; Benoit Schreck; Caroline Victorri-Vigneau
Journal:  Int J Environ Res Public Health       Date:  2021-11-18       Impact factor: 3.390

2.  Interrupted Time Series Analysis of Changes in Zolpidem Use Due to Media Broadcasts.

Authors:  Bo-Ram Yang; Kyu-Nam Heo; Yun Mi Yu; Ga-Bin Yeom; Hye Duck Choi; Ju-Yeun Lee; Young-Mi Ah
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.